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PROBLEM
 More preteens and teens could be receiving the HPV vaccine
 Guidelines recommend ages 9 – 26

 At TCHC, there were largely 2 camps of unvaccinated children I saw:
 Those whose parents held personal beliefs about the vaccines or the immune system
 Those who had not yet been educated on HPV or the vaccine

 Most patients I saw in their 20s had started the vaccine
 The majority of preteens and teens I saw had not received the HPV vaccine
 It may be too late to wait until patients can decide for themselves
 The parents that are lacking education should be identified and receive it
 It may be impossible to change some patient’s personal beliefs

COST & BURDEN IN U.S.
 Cost of HPV infection for both men and women

[1]

 Estimated lifetime total cost ages 15–24 y.o. = $2.9 billion
 Treatment of anogenital warts in all age groups in year 2000 = $167.4 million
 Only HIV is more expensive in terms of STI

 Cost of annual cervical screening and treatment for HPV-related disease
 Estimated avg. $26,415 per 1000 women
 Ages 20 – 29 avg. $51, 863 per 1000 women due to higher prevalence
 Estimated $3.4 billion annually
 90% of cost attributed to strategies for prevention
 Treatment of precancerous lesions
 Routine paps and guideline recommendations

 10% of cost due to treatment of cancer

[2]

COMMUNITY PERSPECTIVE
 MA, 18F, patient at TCHC
 Currently 8 months pregnant and unvaccinated against HPV
 Did not get vaccine because she is afraid of needles
 Was not aware that HPV could cause cancer or how common it is
 Willing to receive vaccine after receiving educational information
 May already be too late for MA given she is already sexually active
 IW, 16F, patient at TCHC
 Currently unvaccinated
 Mother does not want vaccine because she believes “body can fight the infection”


Interestingly she requested a flu vaccine

 IW stated “I’m not of legal age to be sexually active”
 When counseled alone and provided educational information, Ivy changed her mind
 We still need to convince Ivy’s mother

INTERVENTION
 Target under-educated population with patient handout
 Under-educated = does not know about complications of HPV infection

 Educate all patients ages 9 – 26 and their parents
 Specifically address in lay terms 3 main areas:
 Define what HPV is
 Describe what HPV can cause
 Explain why the HPV vaccine is recommended for children

 Provide additional sources of information

RESPONSE
 The most common reason for declining vaccine after receiving

educational information was due to a parent’s personal beliefs
 Among unvaccinated patients who were unaware of HPV complications,
most were willing to receive vaccine after receiving educational
information
 Most preteens and teens were willing to receive vaccine when
counseled alone, but they always deferred to the parent’s decision
 Parent’s personal beliefs against vaccines were wide ranging:
 “lack of safety data”
 “body can fight the infection”
 “not sexually active yet”

EFFECTIVENESS & LIMITATIONS
 The intervention was effective in the population of patients that had not

been informed of the potential complications of HPV infection
 The intervention was not effective when a parent declined due to

personal beliefs against the vaccine
 The results were limited by a small sample size:
 TCHC is not primarily a pediatric clinic
 The length of the intervention thus far has only been 5 weeks

 The intervention is also challenged by the fact that decision making

capacity is deferred to parents in most of the target patients

RECOMMENDATIONS
 Really focus on targeting parents with education when children reach

the age of 9, which is current recommended guideline

 Most persuasive point = increased efficacy when given at younger age

 The intervention is effective in the right population
 Identify those who have not received educational information
 Assume everyone is under-educated until they are vaccinated

 It may be impossible to change some patient’s personal beliefs
 Provide these patients with educational information and support their decision

 Unfortunately some patients are at risk due to their parent’s decisions
 Counsel these patients alone at every visit and provide educational information
 Given time patients whose parents decline may request on their own
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